Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Cancer Chemother Pharmacol. 2008 Nov;62(6):1111-2. doi: 10.1007/s00280-008-0698-6. Epub 2008 Feb 19.

Tumor resensitization to erlotinib following brief substitution of cetuximab.

Author information

  • 1Division of Haematology and Oncology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, Room 802, Administration Block, Pokfulam, Hong Kong, China. repstein@hku.hk

Abstract

Targeted inhibition of epidermal growth factor receptors (EGFR) is becoming a standard anticancer treatment in defined clinical scenarios. EGFR inhibition may be achieved either by small-molecule orally bioavailable tyrosine kinase inhibitors, such as gefitinib or erlotinib, or else by large-molecule receptor antibodies, such as cetuximab or panitumumab. Here, we describe a case of pancreatic cancer in which the small-molecule EGFR antagonist erlotinib was used before and after the EGFR antibody cetuximab, with unexpected potentiation of both toxic and therapeutic sequelae.

PMID:
18283460
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Write to the Help Desk